Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel with Necuparanib or Placebo in Untreated Metastatic Pancreas Ductal Adenocarcinoma

BACKGROUND: Necuparanib, a rationally engineered low molecular weight heparin, combined with gemcitabine/nab-paclitaxel showed an encouraging safety and oncologic signal in a phase Ib trial. This randomized multi-center phase II trial evaluates the addition of necuparanib or placebo to gemcitabine/n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Cancer
Autores principales: O’Reilly, Eileen M., Barone, Diletta, Mahalingam, Devalingam, Bekaii-Saab, Tanios, Shao, Spencer H., Wolf, Julie, Rosano, Molly, Krause, Silva, Richards, Donald A., Yu, Kenneth H., Roach, James M., Flaherty, Keith T., Ryan, David P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8133644/
https://ncbi.nlm.nih.gov/pubmed/32361265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.03.005
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares